Jazz Pharmaceuticals’ (JAZZ) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Thursday,Benzinga reports. The firm currently has a $163.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $166.00.

A number of other research firms have also commented on JAZZ. Wells Fargo & Company lowered their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. TD Cowen decreased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Trading Up 1.3 %

NASDAQ:JAZZ opened at $126.67 on Thursday. The company has a fifty day moving average of $113.65 and a 200 day moving average of $110.73. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $7.66 billion, a P/E ratio of 17.84, a P/E/G ratio of 1.05 and a beta of 0.57.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock valued at $720,160 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of JAZZ. Versant Capital Management Inc increased its holdings in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC lifted its stake in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $33,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.